News
Honors | Wanbangde Pharmaceutical Group once again makes the "Top 100 Traditional Chinese Medicine Enterprises" list—yet again!
Date:
11 May,2023
Preserving the essence without clinging to the past, upholding integrity while embracing innovation—this is our guiding principle. Moving forward, Wanbangde Pharmaceutical will firmly leverage its brand leadership to drive the modernization and industrialization of the traditional Chinese medicine sector, showcasing the clinical value of TCM and injecting dynamic momentum into the high-quality development of the entire中医药 industry!
The conference proudly unveiled eight brand honors for the Chinese medicine industry in 2022. Among them, Wanbangde Pharmaceutical Holding Group Co., Ltd. (stock code: 002082)—the core, wholly-owned subsidiary of Wanbangde Pharmaceutical Group—has once again been recognized as one of the "Top 100 Traditional Chinese Medicine Enterprises," following its inclusion in the list during both 2020 and 2021. Once again, we're proudly listed among the "Top 100 Chinese Patent Medicine Companies 2022"—and this time, we even landed at No. 65, climbing a remarkable 22 spots from last year!
During his speech delivering the award citation as Deputy Secretary-General of the China Association of Traditional Chinese Medicine, Shen Nuo stated that the selection of the "Top 100 Traditional Chinese Medicine Enterprises of 2022" was based on a comprehensive evaluation of three key indicators: main business revenue, total profit, and R&D investment. Specifically, main business revenue and total profit each accounted for 40% of the weighting, while corporate R&D investment made up the remaining 20%. The final rankings were determined by aggregating scores across these three dimensions. Additionally, the selection process adhered to a strict "negative-list veto" principle—any enterprise failing to meet even one criterion would be immediately disqualified. After thorough review by the Association's Brand Comprehensive Group and approval by the Chairman's Office Meeting, the final list of winners was officially announced to the public. Overall, the entire selection process was both scientifically sound and rigorously conducted.
Preserving the essence without clinging to the past, upholding integrity while embracing innovation—this is our guiding principle. Moving forward, Wanbangde Pharmaceutical will firmly leverage its brand leadership to drive forward the modernization and industrialization of the traditional Chinese medicine sector, highlighting the clinical value of TCM and injecting dynamic momentum into the high-quality development of the entire中医药 industry!
Related Recommendations